|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
CTG004523903 |
003 |
DE-627 |
005 |
20230425174854.0 |
007 |
cr uuu---uuuuu |
008 |
210507s2021 xx |||||o 00| ||eng c |
035 |
|
|
|a (DE-627)CTG004523903
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)CTRI/2020/10/028635
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)NIL
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
245 |
1 |
0 |
|a use of VIRUNIL an Ayurvedic medicie as a supportive treatment in management of COVID-19.
|b Clinical evaluation of Virunil a standardized ayurvedic herbal compound as an adjuvant in management of COVID-19
|
264 |
|
1 |
|c 2021
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 26-10-2020, Last updated: 2022-11-24
|
650 |
|
4 |
|a Medical Condition: Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: J99- Respiratory disorders in diseasesclassified elsewhere
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 2/Phase 3
|
650 |
|
4 |
|a Recruitment Status: Not yet recruiting
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2021) vom: 24. Nov.
|
773 |
1 |
8 |
|g year:2021
|g day:24
|g month:11
|
856 |
4 |
0 |
|u http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48783
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
912 |
|
|
|a SSG-OLC-PHA
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2021
|b 24
|c 11
|